Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 1.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 542,284 shares of the biopharmaceutical company’s stock after purchasing an additional 7,764 shares during the period. Fisher Asset Management LLC’s holdings in Cytokinetics were worth $28,633,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. J.Safra Asset Management Corp increased its holdings in Cytokinetics by 642.3% in the second quarter. J.Safra Asset Management Corp now owns 527 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 456 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Cytokinetics by 65.6% in the 3rd quarter. UMB Bank n.a. now owns 601 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 238 shares during the period. Blue Trust Inc. increased its stake in Cytokinetics by 225.9% in the 3rd quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 680 shares in the last quarter. Values First Advisors Inc. acquired a new position in Cytokinetics during the third quarter worth $54,000. Finally, Bessemer Group Inc. boosted its position in Cytokinetics by 25,100.0% during the first quarter. Bessemer Group Inc. now owns 1,260 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 1,255 shares in the last quarter.

Insider Buying and Selling at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 7,384 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $57.01, for a total transaction of $420,961.84. Following the completion of the sale, the executive vice president now owns 122,920 shares of the company’s stock, valued at approximately $7,007,669.20. This represents a 5.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of Cytokinetics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $57.03, for a total transaction of $285,150.00. Following the transaction, the chief executive officer now directly owns 397,456 shares in the company, valued at approximately $22,666,915.68. This trade represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,378 shares of company stock worth $3,880,287 in the last quarter. 3.40% of the stock is owned by insiders.

Cytokinetics Stock Performance

Cytokinetics stock opened at $52.02 on Wednesday. The stock has a fifty day moving average price of $53.47 and a 200 day moving average price of $54.57. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 52 week low of $30.68 and a 52 week high of $110.25. The firm has a market capitalization of $6.14 billion, a P/E ratio of -9.67 and a beta of 0.78.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.09). The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $1.21 million. During the same quarter in the prior year, the firm posted ($1.35) EPS. Cytokinetics’s revenue for the quarter was up 22.5% on a year-over-year basis. Equities research analysts anticipate that Cytokinetics, Incorporated will post -5.25 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CYTK shares. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a research report on Monday, November 18th. JMP Securities restated a “market outperform” rating and set a $78.00 target price on shares of Cytokinetics in a report on Wednesday, September 4th. Mizuho upped their price target on shares of Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Needham & Company LLC reissued a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a research note on Wednesday, November 20th. Finally, The Goldman Sachs Group downgraded Cytokinetics from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $85.00 to $60.00 in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $83.93.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.